---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-23-000125"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:02:50.930363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q3 net income $17.6M ($0.28 EPS); cash $256.4M; TAMARACK enrollment ahead of schedule

## Summary
- Net income $17.6M ($0.28 diluted EPS) vs net loss $24.8M in Q3 2022; revenue $10.4M down from $41.7M.
- Cash and marketable securities $256.4M; expect cash runway into 2026; received $15.7M Gilead milestone and $50M Sanofi milestone in Q3.
- Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule; data readout expected H1 2024.
- Initiated LORIKEET Phase 2 of lorigerlimab in mCRPC; IND submitted for MGC026 ADC; Phase 1 to start Q1 2024.
- R&D expenses $30.1M (down from $48.2M); SG&A $12.4M (down from $15.4M); shares outstanding 62.0M.

## SEC filing metadata
- accession: 0001125345-23-000125
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/0001125345-23-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/mgnx-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-23-000125
- JSON: https://secwatch.observer/filing/0001125345-23-000125.json
- Plain text: https://secwatch.observer/filing/0001125345-23-000125.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported the quarter ended September 30, 2023 results: revenue $10.4 million.
  - Period: the quarter ended September 30, 2023
  - Revenue: $10.4 million
  - Result: reported results
  source text: Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000125/0001125345-23-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.